CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 100.0%

Compliant submissions 1

Incompliant submissions 0

Total trials 1

My Organizations' Clinical Trials

Showing 250 of 279 entries

View as:

NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases

Phase: N/A Priority: Normal

NCT ID: NCT01370213 Org: User:

Start: 09/30/11 End: 04/30/17 Due: 04/30/18

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

Phase: N/A Priority: Normal

NCT ID: NCT03579875 Org: User:

Start: 11/13/18 End: 01/05/29 Due: 01/05/30

QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML

Phase: N/A Priority: Normal

NCT ID: NCT03365661 Org: User:

Start: 10/30/18 End: 01/01/23 Due: 01/01/24

Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma

Phase: N/A Priority: Normal

NCT ID: NCT00005987 Org: User:

Start: 08/31/00 End: 07/31/03 Due: 07/31/04

AHN-12 Biodistribution in Advanced Leukemia

Phase: N/A Priority: Normal

NCT ID: NCT01207076 Org: User:

Start: 12/31/13 End: 07/31/14 Due: 07/31/15

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases

Phase: N/A Priority: Normal

NCT ID: NCT03367546 Org: User:

Start: 07/02/18 End: 12/19/22 Due: 12/19/23

Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids

Phase: N/A Priority: Normal

NCT ID: NCT05123040 Org: User:

Start: 06/05/23 End: 09/30/28 Due: 09/30/29

Impact of Low Nicotine Cigarette Messaging on Perceptions and Cigarette Choices

Phase: N/A Priority: Normal

NCT ID: NCT04740008 Org: User:

Start: 04/20/21 End: 08/24/22 Due: 08/24/23

PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation

Phase: N/A Priority: Normal

NCT ID: NCT05120570 Org: User:

Start: 03/17/22 End: 03/31/28 Due: 03/31/29

Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies

Phase: N/A Priority: Normal

NCT ID: NCT02991898 Org: User:

Start: 02/16/17 End: 06/20/19 Due: 06/20/20

Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Phase: N/A Priority: Normal

NCT ID: NCT00287859 Org: User:

Start: 08/31/04 End: 12/31/06 Due: 12/31/07

Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal

NCT ID: NCT00005985 Org: User:

Start: 08/31/00 End: 02/28/07 Due: 02/28/08

Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism

Phase: N/A Priority: Normal

NCT ID: NCT00668564 Org: User:

Start: 03/31/08 End: 02/28/10 Due: 02/28/11

Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs

Phase: N/A Priority: Normal

NCT ID: NCT01033552 Org: User:

Start: 01/31/10 End: 08/12/21 Due: 08/12/22

Effect of Kava on Anxiety and Stress in Cancer Survivors

Phase: N/A Priority: Normal

NCT ID: NCT06213298 Org: User:

Start: 06/20/24 End: 11/01/26 Due: 11/01/27

Vegetable Intake Effect on Heterocyclic Amine Metabolism

Phase: N/A Priority: Normal

NCT ID: NCT04882423 Org: User:

Start: 09/19/13 End: 08/31/15 Due: 08/31/16

Busulfan and Cyclophosphamide Followed By ALLO BMT

Phase: N/A Priority: Normal

NCT ID: NCT01685411 Org: User:

Start: 01/31/13 End: 02/10/20 Due: 02/10/21

Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)

Phase: N/A Priority: Normal

NCT ID: NCT01106950 Org: User:

Start: 07/31/10 End: 12/31/12 Due: 12/31/13

T-Cell Depleted Double UCB for Refractory AML

Phase: N/A Priority: Normal

NCT ID: NCT01464359 Org: User:

Start: 10/31/11 End: 10/31/13 Due: 10/31/14

Remote Trial - Tobacco Product Standard (VLNC)

Phase: N/A Priority: Normal

NCT ID: NCT06442384 Org: User:

Start: 09/11/24 End: 04/07/25 Due: 04/07/26

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Phase: N/A Priority: Normal

NCT ID: NCT03314974 Org: User:

Start: 03/30/18 End: 06/10/27 Due: 06/10/28

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Phase: N/A Priority: Normal

NCT ID: NCT05735717 Org: User:

Start: 05/11/23 End: 11/30/30 Due: 11/30/31

Physical Rehabilitation Evaluation and Optimal Physical Therapy (PRE-OPT)

Phase: N/A Priority: Normal

NCT ID: NCT04225572 Org: User:

Start: 12/27/17 End: 12/31/26 Due: 12/31/27

BAriaTric Surgery After Breast Cancer Treatment (BATS)

Phase: N/A Priority: Normal

NCT ID: NCT03946423 Org: User:

Start: 06/30/25 End: 02/28/26 Due: 02/28/27

Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

Phase: N/A Priority: Normal

NCT ID: NCT00345865 Org: User:

Start: 08/24/05 End: 06/28/19 Due: 06/28/20

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases	NCT01370213	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2011-09-30	2017-04-30	2018-04-30	-	-	2025-07-14
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders	NCT03579875	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2018-11-13	2029-01-05	2030-01-05	-	-	2025-07-14
QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML	NCT03365661	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2018-10-30	2023-01-01	2024-01-01	-	-	2025-07-14
Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma	NCT00005987	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2000-08-31	2003-07-31	2004-07-31	-	-	2025-07-14
AHN-12 Biodistribution in Advanced Leukemia	NCT01207076	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2013-12-31	2014-07-31	2015-07-31	-	-	2025-07-14
Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases	NCT03367546	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2018-07-02	2022-12-19	2023-12-19	-	-	2025-07-14
Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids	NCT05123040	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2023-06-05	2028-09-30	2029-09-30	-	-	2025-07-14
Impact of Low Nicotine Cigarette Messaging on Perceptions and Cigarette Choices	NCT04740008	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2021-04-20	2022-08-24	2023-08-24	-	-	2025-07-14
PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation	NCT05120570	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2022-03-17	2028-03-31	2029-03-31	-	-	2025-07-14
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies	NCT02991898	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2017-02-16	2019-06-20	2020-06-20	-	-	2025-07-14
Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer	NCT00287859	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2004-08-31	2006-12-31	2007-12-31	-	-	2025-07-14
Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma	NCT00005985	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2000-08-31	2007-02-28	2008-02-28	-	-	2025-07-14
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism	NCT00668564	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2008-03-31	2010-02-28	2011-02-28	-	-	2025-07-14
Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs	NCT01033552	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2010-01-31	2021-08-12	2022-08-12	-	-	2025-07-14
Effect of Kava on Anxiety and Stress in Cancer Survivors	NCT06213298	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2024-06-20	2026-11-01	2027-11-01	-	-	2025-07-14
Vegetable Intake Effect on Heterocyclic Amine Metabolism	NCT04882423	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2013-09-19	2015-08-31	2016-08-31	-	-	2025-07-14
Busulfan and Cyclophosphamide Followed By ALLO BMT	NCT01685411	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2013-01-31	2020-02-10	2021-02-10	-	-	2025-07-14
Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)	NCT01106950	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2010-07-31	2012-12-31	2013-12-31	-	-	2025-07-14
T-Cell Depleted Double UCB for Refractory AML	NCT01464359	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2011-10-31	2013-10-31	2014-10-31	-	-	2025-07-14
Remote Trial - Tobacco Product Standard (VLNC)	NCT06442384	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2024-09-11	2025-04-07	2026-04-07	-	-	2025-07-14
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders	NCT03314974	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2018-03-30	2027-06-10	2028-06-10	-	-	2025-07-14
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies	NCT05735717	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2023-05-11	2030-11-30	2031-11-30	-	-	2025-07-14
Physical Rehabilitation Evaluation and Optimal Physical Therapy (PRE-OPT)	NCT04225572	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2017-12-27	2026-12-31	2027-12-31	-	-	2025-07-14
BAriaTric Surgery After Breast Cancer Treatment (BATS)	NCT03946423	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2025-06-30	2026-02-28	2027-02-28	-	-	2025-07-14
Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma	NCT00345865	Masonic Cancer Center, University of Minnesota	user2@example.com	None	2005-08-24	2019-06-28	2020-06-28	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance